Search This Blog

Monday, March 16, 2026

Annovis Phase 3 Alzheimer’s trial 65% enrolled, 6‑month DSMB positive safety, cash runway into Q3 2026

 

Annovis Bio says buntanetap Phase 3 Alzheimer’s trial 65% enrolled, 6‑month DSMB finds positive safety, cash runway into Q3 2026

  • Reported fiscal Q4 2025 non-GAAP EPS $-0.39 (+9% YoY) and revenue $0, missing EPS but beating revenue estimates.
  • Fiscal 2025 results release emphasized buntanetap Phase 3 progress and the company's cash runway into Q3 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)